We demonstrated that PDE4B but not PDE4D blockage is essential to obtain a therapeutic effect in animal models of immune-mediated hepatitis, autoimmune rheumatoid arthritis, and endotoxemia. This evidence concerns the gene PDE4B and serum lipopolysaccharide activity.